SCIENCE & INNOVATIONS
Age-Related Macular Degeneration (AMD) is a complex disease leading to vision loss, with no effective treatment for early-intermediate stages,
and only limited options exist for advanced stages. AMD is characterized by the death of photoreceptors and Retinal Pigment Epithelium (RPE) cells, which provide metabolic support to photoreceptors.
Despite increased understanding, existing therapies offer limited benefits and fail to halt disease progression. There is an urgent need for a treatment that can prevent macular damage and the development of advanced stages.
Our innovative technology targets the mechanism underlying AMD pathogenesis - the accumulation of cellular damage and aging of the retina. For the first time, our drug aims to halt the progression of dry AMD by addressing this crucial pathway, offering a promising solution to this unmet medical need.
OphtiMed Rx is a preclinical startup developing an anti-aging therapy for dry AMD
WHAT WE DO
Central vision loss
OUR INNOVATIVE SOLUTION
OM-301
A Potent Compound Protecting RPE Cells from Senescence
Our potent drug candidate, OM-301, protects Retinal cells from senescence and aims to halt AMD progression in early-intermediate stages.
Through thorough preclinical studies, we've validated its senescence-protective activity on RPE cells and impact on key disease characteristics in vivo and in vitro, demonstrating its potential as a solution for early-intermediate dry AMD.
We’ve completed key elements of preclinical and CMC activities, and are currently preparing for a pre-IND meeting with the FDA to begin formal development of our anti-senescence drug for phase I clinical setting.
GLOBAL IMPACT AND TREATMENT
GLOBAL BURDEN OF AMD
AMD constitutes almost half of all cases of blindness or partial sight globally, resulting in substantial social and economic burdens.
CURRENT TREATMENT GAP
Dry AMD, affecting 85-90% of AMD patients, lacks an effective therapy due to its intricate and chronic nature. Addressing this treatment gap requires innovative strategies.
ADVANCEMENTS NEEDED
The transition from early to advanced dry AMD or wet AMD remains poorly understood. Innovative therapeutic approaches are essential to prevent and treat this debilitating disease.
SOCIOECONOMIC IMPACT
Addressing sight loss in an aging population carries health benefits and has profound social and economic implications.
Targeting RPE Cell Senescence:
A Novel Approach
AMD is characterized by the deterioration of the macula, the central portion of the retina responsible for central vision. RPE cell senescence plays a significant role in AMD development and progression. OM-301 is designed to protect RPE cells from senescence, offering a unique approach to halt disease progression.
Our research has yielded encouraging results, demonstrating OM-301's ability to protect RPE cells from senescence and its positive impact on key disease characteristics in vivo and in vitro.
Advancing to Clinical Development
Building on our preclinical findings, we've completed key preclinical and CMC activities. We are currently preparing for a pre-IND meeting with the FDA to begin formal development of our anti-senescence drug for phase I clinical trials.
OM-301 offers the potential for long intervals between intravitreal injections, as senescent cells take time to reform. By eliminating senescent cells, OM-301 maintains efficacy over time, enabling less frequent administration and reducing the treatment burden on patients.
Robust Drug Screening Cellular Platforms
We've established two robust cellular systems for RPE senescence. We utilize these systems as platforms for screening drug candidates that work in a similar Mechanism Of Action (MOA).
We aim to create a portfolio of agents that can combat dry AMD and other retinal degeneration pathologies.
IP Portfolio covering compound use and formulation
Our IP Portfolio includes patents covering compound use and formulation, forming a powerful foundation. With granted patents in key markets and ongoing applications, it fosters collaboration and deters competitors.
A proactive IP management approach strengthens our defense against infringement, highlighting our commitment to innovation.
FUTURE OUTLOOK
At OphtiMed Rx, we're actively establishing strategic partnerships and navigating regulatory landscapes to propel our vision forward. With a dedicated focus on securing critical funding, we are steadfastly working towards completing the necessary activities to initiate first-in-human (FIH) clinical trials, expected by mid-2025.
Join Us on This Transformative Journey
As we move closer to clinical translation, we seek collaborative opportunities, support, and investment to accelerate our mission. Together, we can make a profound impact on the lives of individuals affected by dry age-related macular degeneration (AMD). Join us on this transformative journey as we strive to deliver innovative solutions that could redefine eye care.
Driving Innovation through Collaboration
We believe that collaboration is key to driving innovation. By fostering strategic partnerships and leveraging the collective expertise of industry leaders, researchers, and investors, we can unlock new frontiers in eye care. Together, we can overcome challenges, navigate regulatory hurdles, and ultimately bring life-changing therapies to those in need.
